trending Market Intelligence /marketintelligence/en/news-insights/trending/MOx8yTIc1jvB3fC8kRu2vw2 content esgSubNav
In This List

Sangamo transfers gene therapy SB-525 to co-developer Pfizer

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Sangamo transfers gene therapy SB-525 to co-developer Pfizer

Sangamo Therapeutics Inc. has transferred SB-525 to Pfizer Inc., its partner in developing the gene therapy for treating the bleeding disorder hemophilia A.

As per their agreement, Richmond, Calif.-based Sangamo handled the early- and mid-stage trials of the drug while Pfizer will take charge of the drug's late-stage trial, expected in 2020.

SB-525 is an investigational gene therapy for severe hemophilia A, a genetic bleeding disorder in which the blood does not clot normally due to the absence or low levels of factor VIII, a protein needed to form blood clots.

Sangamo received $25 million as a milestone payment from New York-based pharmaceutical giant Pfizer.

Sangamo is eligible for total milestone payments of up to $300 million for developing and commercializing SB-525 and tiered royalties from the low teens up to 20% of net yearly sales of SB-525. The company will also receive up to $175 million for additional Hemophilia A gene therapies it co-develops with Pfizer.

The U.S. Food and Drug Administration tagged Sangamo-Pfizer's SB-525 as a regenerative medicine advanced therapy in July and gave it orphan-drug and fast-track designations in 2017.

The gene therapy has also received an orphan medicinal product status from the European Medicines Agency.